Qiming Venture Partners’ Post

We are pleased to share positive interim results from our Phase 1 clinical study of VQ-101, a small molecule allosteric activator of GCase. In healthy volunteers in Phase 1a, VQ-101 demonstrated good tolerability, robust lysosomal GCase activation, and pharmacokinetics consistent with once daily dosing. The study, conducted at Centre for Human Drug Research, has advanced to the Phase 1b portion in patients with Parkinson’s disease. https://lnkd.in/eqRzbQct

❗️Announcement❗️   We're thrilled to introduce Mitchell Steiner, MD, FACS, Chief Executive Officer of Veru Inc., as the newest addition to our expert speaker faculty!   Unveil the full speaker faculty here - https://ter.li/of61al   Attendees are gearing up for a groundbreaking presentation on advancing enobosarm, an oral novel selective androgen receptor modulator, to avoid muscle loss and augment fat loss when combined with a glucagon-like peptide-1 receptor agonist drug for potentially higher quality weight loss.   Explore Mitchell's talk in more detail by downloading full agenda - https://ter.li/of61al   The 𝗚𝗟𝗣-𝟭-𝗕𝗮𝘀𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗦𝘂𝗺𝗺𝗶𝘁 is a truly unique forum, dedicated to advancing GLP-1s, while combatting muscle deterioration. Mitchell Steiner emphasizes that:   “𝘞𝘦 𝘩𝘢𝘷𝘦 𝘳𝘦𝘢𝘤𝘩𝘦𝘥 𝘢 𝘴𝘪𝘨𝘯𝘪𝘧𝘪𝘤𝘢𝘯𝘵 𝘮𝘪𝘭𝘦𝘴𝘵𝘰𝘯𝘦 𝘪𝘯 𝘵𝘩𝘦 𝘣𝘢𝘵𝘵𝘭𝘦 𝘢𝘨𝘢𝘪𝘯𝘴𝘵 𝘰𝘣𝘦𝘴𝘪𝘵𝘺. 𝘎𝘓𝘗-1 𝘢𝘨𝘦𝘯𝘵𝘴 𝘢𝘳𝘦 𝘷𝘦𝘳𝘺 𝘦𝘧𝘧𝘦𝘤𝘵𝘪𝘷𝘦 𝘸𝘦𝘪𝘨𝘩𝘵 𝘭𝘰𝘴𝘴 𝘥𝘳𝘶𝘨𝘴, 𝘣𝘶𝘵 𝘮𝘶𝘴𝘤𝘭𝘦 𝘪𝘴 𝘴𝘢𝘤𝘳𝘪𝘧𝘪𝘤𝘦𝘥. 𝘛𝘩𝘦 𝘵𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤 𝘴𝘵𝘳𝘢𝘵𝘦𝘨𝘺 𝘰𝘧 𝘵𝘩𝘦 𝘯𝘦𝘹𝘵 𝘨𝘦𝘯𝘦𝘳𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 𝘥𝘳𝘶𝘨𝘴 𝘴𝘩𝘰𝘶𝘭𝘥 𝘧𝘰𝘤𝘶𝘴 𝘰𝘯 𝘵𝘩𝘦 𝘲𝘶𝘢𝘭𝘪𝘵𝘺 𝘰𝘧 𝘵𝘩𝘦 𝘸𝘦𝘪𝘨𝘩𝘵 𝘭𝘰𝘴𝘴, 𝘱𝘳𝘦𝘧𝘦𝘳𝘦𝘯𝘵𝘪𝘢𝘭𝘭𝘺 𝘳𝘦𝘮𝘰𝘷𝘪𝘯𝘨 𝘧𝘢𝘵 𝘸𝘩𝘪𝘭𝘦 𝘱𝘳𝘦𝘴𝘦𝘳𝘷𝘪𝘯𝘨 𝘮𝘶𝘴𝘤𝘭𝘦. 𝘛𝘩𝘦 𝘎𝘓𝘗-1-𝘉𝘢𝘴𝘦𝘥 𝘛𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤 𝘚𝘶𝘮𝘮𝘪𝘵 𝘱𝘳𝘰𝘷𝘪𝘥𝘦𝘴 𝘢 𝘧𝘰𝘳𝘶𝘮 𝘵𝘰 𝘢𝘥𝘷𝘢𝘯𝘤𝘦 𝘵𝘩𝘪𝘴 𝘴𝘵𝘳𝘢𝘵𝘦𝘨𝘺.” Will you be uniting with 𝟲𝟬+ 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗲𝘅𝗽𝗲𝗿𝘁𝘀 this May, all committed to 𝘀𝘁𝗮𝘆𝗶𝗻𝗴 𝗮𝗵𝗲𝗮𝗱 𝗼𝗳 𝘁𝗵𝗲 𝗰𝘂𝗿𝘃𝗲?   #GLP1BasedTherapeuticsSummit

🔬 Have you signed up yet? Are you ready to delve even deeper into the realm of central nervous system (CNS) therapies? Our Chief Scientist, francesca cormack alongside Altasciences will explore the crucial stages of drug development for CNS-active compounds. Reserve your spot now: https://lnkd.in/eMRuh5Xc 💡 Don't miss out on what promises to be another illuminating webinar! Here's what's in store: - Unravelling the essential cognitive and pharmacodynamic tests vital for your new CNS-active drug. - Identifying the most pertinent and reliable populations for testing, ensuring the utmost precision in your research. - Harnessing cognitive and pharmacodynamic data adeptly for seamless drug development and strategic regulatory planning. Secure your spot today to glean invaluable insights from some of the foremost experts in CNS research. #CNS #webinar #digitalbiomarkers #cognitivetesting

🔬 Dive deep into the world of central nervous system (CNS) therapies with our Chief Scientist, francesca cormack! Join us in partnership with Altasciences as we unravel the critical stages of drug development for CNS-active compounds. Sign up here: https://lnkd.in/eMRuh5Xc 💡 In this exclusive webinar, we'll uncover: - Determining the essential cognitive and pharmacodynamic tests crucial for your new CNS-active drug. - Identifying the most relevant and valid populations for testing, ensuring precision in your research. - Leveraging cognitive and pharmacodynamic data effectively for seamless drug development and regulatory planning. Sign up today to hear from some of the brightest minds in CNS research: https://lnkd.in/eMRuh5Xc #CNS # webinar #digitalbiomarkers #cognitivetesting

Bristol Myers Squibb Presents the Long-Term P-III (MAVA-LTE) Trial Data of Camzyos to Treat Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) #bms #camzyos #symptomaticobstructivehypertrophiccardiomyopathy #clinicaltrial #phase3 #mavalte

Johnson & Johnson's experimental autoimmune drug, nipocalimab, demonstrated success in a Phase 3 study for treating generalized myasthenia gravis, offering significant benefits compared to a placebo. The drug works by targeting disease-causing antibodies, leading to improved daily functioning and quality of life for patients. J&J is optimistic about the potential approval of nipocalimab for this condition and aims to expand its usage across multiple indications, projecting substantial revenue growth. #AutoimmuneDisease #Nipocalimab #MyastheniaGravis #AntibodyTherapy #HealthcareInnovation Read more here: https://lnkd.in/egiNWQNN BioMedHack.com is your leading source for the latest news, breakthroughs, and insights in medicine, biohacking, and alternative medicine. Our mission is to help you live healthier and longer by bringing you cutting-edge information and expert advice. Follow us on Facebook, Instagram, and X.

If we are really looking into these precision medicine initiatives- what we are doing right now is fishing for those patients who have a chance to respond to immune therapy and make sure they get it. As for the rest, it's stable disease and the hope for the occasional responder and gratefulness for any life saved. So basically, it's super-easy to be snarky and criticise and lament we should have just *prevented it all*. The kicker is this- this is the worst-off cancer patient population there is. Those who have been through all lines of treatment- and the cohorts are full of those cancers with no good treatments to start with. These are the people who are usually sent off to some more or less reasonable Ph1- or directly to palliative care to hopefully die at least without being in pain. This is the stage of disease that gives cancer its bad reputation and causes the fear- it makes it the Voldemort where people only talk about the 'c-word'. After having been through this with my husband and having become a person where people go when there's nothing left- I think it's down to 2 things: 1. we aren't particularly good at dealing with our own mortality in general and working close to death gives you a lot of pause for thought. 2. it's a clear demonstration of what we have not understood and cannot control in medicine and that's a particularly tough one when you are a clinician or a cancer researcher. And yes, we should prevent whatever is possible. But we cannot prevent everything. And we cannot undo the past- what we see now is the outcomes of prevention gone wrong for decades. And with age being one of the biggest risk factors for cancer, ageing societies don't have a good way out anyway. So the real question is whether we have the guts to tackle a setting with very little happy survivor stories. Or whether we somehow deep down think that we just aren't smart enough to crack this.

Immunotherapy Vol. 15, No. 18 - Plain Language Summary of Publication A Plain Language Summary describing how two different concentrations of GP2017, a biosimilar adalimumab medicine, are associated with similar drug levels within the body https://lnkd.in/e_AZtfHK

Evidence for the feasibility, early efficacy and safety of incorporating comprehensive #GenomicProfiling into clinical practice to provide #personalised treatments based on Drug Rediscovery Protocol-like Clinical Trials (DLCTs) was presented at #ESMO24. DLCTs explore the effects of #biomarker-driven treatments outside their approved indication(s) across a broad range of tumour types, thus enabling the study of #PrecisionOncology in large patient numbers, according to Vivek Subbiah, MD. 👇Read the full article on the #ESMODailyReporter https://ow.ly/tVNg50ToglA

Novo Nordisk’s semaglutide has achieved positive outcomes in a Phase 3 trial for metabolic dysfunction-associated steatohepatitis (previously known as nonalcoholic steatohepatitis).   The Essence trial demonstrated significant improvements in liver fibrosis and resolution of steatohepatitis, successfully meeting primary endpoints. With this breakthrough, Novo Nordisk aims to file for regulatory approval in the U.S. and Europe by 2025.   These promising results highlight the expanding role of GLP-1 therapies in many indications, including this complex field, which has limited treatment options.   Read more here: https://lnkd.in/ed5bvzDk   Find the clinical evidence for semaglutide on DRUGDOCS®: https://lnkd.in/gjy4C8QW   #MASH #NAFLD #GLP1 #LiverDisease